Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Therapeutic Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Diridavumab (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza A virus infections
- Focus Therapeutic Use
- 19 Nov 2020 Results published in the Clinical Infectious Diseases
- 25 Oct 2020 Results presented at the IDWeek 2020
- 01 Dec 2018 Status changed from recruiting to completed.